948 related articles for article (PubMed ID: 28239873)
1. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
2. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
6. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
7. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
9. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
Radin M; Sciascia S; Roccatello D; Cuadrado MJ
BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
[TBL] [Abstract][Full Text] [Related]
10. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
[TBL] [Abstract][Full Text] [Related]
11. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
[TBL] [Abstract][Full Text] [Related]
13. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
[TBL] [Abstract][Full Text] [Related]
14. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW
J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251
[TBL] [Abstract][Full Text] [Related]
18. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
20. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Guerra Veloz MF; Vázquez Morón JM; Belvis Jiménez M; Pallarés Manrique H; Valdés Delgado T; Castro Laria L; Maldonado Pérez B; Benítez Roldán A; Perea Amarillo R; Merino V; Caunedo Álvarez Á; Argüelles Arias F
Rev Esp Enferm Dig; 2018 Sep; 110(9):564-570. PubMed ID: 29893581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
